|
Back to Home » March 2021 News » Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease |
Vicore Pharma's drug candidate C21 dilates peripheral resistance vessels in fibrotic disease |
March 11, 2021
GOTHENBURG, Sweden, March 11, 2021 /PRNewswire/ -- Vicore Pharma Holding AB (publ), a pharmaceutical company developing innovative medicines for severe lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces top line data from a phase II study of its oral angiotensin...
Source URL: https://www.prnewswire.com:443/news-releases/vicore-pharmas-drug-candidate-c21-dilates-peripheral-resistance-vessels-in-fibrotic-disease-301245265.html
|
|
|
|
